Find Gacyclidine manufacturers, exporters & distributors on PharmaCompass

Gacyclidine

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 68134-81-6, Gacyclidine [inn], 1-[(1r,2s)-2-methyl-1-thiophen-2-ylcyclohexyl]piperidine, 1-(cis-2-methyl-1-(2-thienyl)cyclohexyl)piperidine, 9290nd070r, Gk-11

Molecular Formula

C₁₆H₂₅NS

Molecular Weight

263.4 g/mol

InChI Key

DKFAAPPUYWQKKF-GOEBONIOSA-N

FDA UNII

9290ND070R

Gacyclidine has been used in trials studying the treatment of Tinnitus.

1 2D Structure

Gacyclidine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-[(1R,2S)-2-methyl-1-thiophen-2-ylcyclohexyl]piperidine

2.1.2 InChI

InChI=1S/C16H25NS/c1-14-8-3-4-10-16(14,15-9-7-13-18-15)17-11-5-2-6-12-17/h7,9,13-14H,2-6,8,10-12H2,1H3/t14-,16+/m0/s1

2.1.3 InChI Key

DKFAAPPUYWQKKF-GOEBONIOSA-N

2.1.4 Canonical SMILES

CC1CCCCC1(C2=CC=CS2)N3CCCCC3

2.1.5 Isomeric SMILES

C[C@H]1CCCC[C@@]1(C2=CC=CS2)N3CCCCC3

2.2 Other Identifiers

2.2.1 UNII

9290ND070R

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Gk 11

2. Gk-11

3. Gk11

4. Methyl-2-r-(piperidine-1-)-1-(thienyl-2)1-cyclohexene

2.3.2 Depositor-Supplied Synonyms

1. 68134-81-6

2. Gacyclidine [inn]

3. 1-[(1r,2s)-2-methyl-1-thiophen-2-ylcyclohexyl]piperidine

4. 1-(cis-2-methyl-1-(2-thienyl)cyclohexyl)piperidine

5. 9290nd070r

6. Gk-11

7. Nst-001

8. Unii-9290nd070r

9. Oto-311

10. (+)-gacyclidine

11. Methyl-2-r-(piperidine-1-)-1-(thienyl-2)1-cyclohexene

12. Gacyclidine [who-dd]

13. 1-[(1r,2s)-2-methyl-1-(thiophen-2-yl)cyclohexyl]piperidine

14. Schembl397836

15. Dtxsid30218313

16. Piperidine, 1-(2-methyl-1-(2-thienyl)cyclohexyl)-, Cis-

17. Zinc4213419

18. Akos016010755

19. Db13096

20. Q13560447

21. Piperidine, 1-((1r,2s)-2-methyl-1-(2-thienyl)cyclohexyl)-, Rel-

2.4 Create Date

2005-08-09

3 Chemical and Physical Properties

Molecular Formula	C₁₆H₂₅NS
Molecular Weight	263.4 g/mol
XLogP3	4.4
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	2
Exact Mass	263.17077098 g/mol
Monoisotopic Mass	263.17077098 g/mol
Topological Polar Surface Area	31.5 Å²
Heavy Atom Count	18
Formal Charge	0
Complexity	274
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Neuroprotective Agents

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)

Excitatory Amino Acid Antagonists

Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)

Drugs in Development